Year None 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2014 Nov 10, 2026 PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights Nov 04, 2026 Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026 Oct 05, 2026 PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors Sep 08, 2026 PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer Aug 31, 2026 PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities Aug 31, 2026 PMV Pharma Announces Proposed Public Offering of Securities Aug 31, 2026 PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial Aug 14, 2026 PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights May 12, 2026 PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights Apr 22, 2026 PMV Pharmaceuticals Announces Board Chair Transition Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 12